Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
entinostat + exemestane
- Development stage
- Phase 3
- Lead developer
- Syndax Pharmaceuticals
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Entinostat + exemestane is a combination therapy consisting of entinostat, an oral selective class I histone deacetylase (HDAC) inhibitor, and exemestane, an aromatase inhibitor. This combination is designed to overcome endocrine therapy resistance in hormone receptor-positive (HR+) advanced or metastatic breast cancer. Entinostat works by targeting epigenetic mechanisms that contribute to resistance to hormonal therapies, while exemestane reduces estrogen production by inhibiting the aromatase enzyme.
02
Targets
AR (Adrenergic receptors)CYP19A1 (Aromatase)HDAC (HDAC family)
Beyond the preview
Go deeper on entinostat + exemestane.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on entinostat + exemestane.